Last updated on November 2017

Migraine (Pediatric)


Brief description of study

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years.

Eligibility Criteria:

Each child must have a responsible trained adult with knowledge of the conduct of the study and must be available to supervise migraine treatment and study requirements. Parent or legal guardian is able to provide written informed consent and subject is able to provide written assent.

Clinical Study Identifier: TX133687

Contact Investigators or Research Sites near you

Start Over

Northwest Clinical Research Center

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »